蚓激酶治疗心肌梗死合并高纤维蛋白原血症43例疗效观察

用蚓激酶治疗心肌梗死合并高纤维蛋白原血症４３ 例，分别于用药前、用药后测定血纤维蛋白原。发现用蚓激酶２ 周后，血纤维蛋白原质量浓度明显下降〔（４ ．３３ ±１ ．０９） ｇ／Ｌ〕，与用药前〔（５ ．３４ ±０ ．８９） ｇ／Ｌ〕相比有显著性差异（ Ｐ＜ ０ ．０５） 。用药３ 周后纤维蛋白原进一步降低〔（３ ．７１ ±０ ．４８） ｇ／Ｌ〕，与用药前和用药后２ 周相比均有显著性差异（ 均Ｐ＜ ０ ．０５） 。用药后２ 周和３ 周，蚓激酶组与对照组相比亦有显著性差异（ 均Ｐ＜ ０ ．０５） ，且无明显不良反应。结果提示蚓激酶治疗高纤维蛋白原血症有一定疗效，可以考虑做为冠心病的预防用药。

Lumbrokinase in Treatment of Patients with Hyperfibrinogenemia of Coronary Atherogenesis Disease

The aim of this study is to evaluate the effects of lumbrokinase on hyperfibrinogenemia.Patients with hyperfibrinogenemia were orally ad ministered lum brokinase six tablets per day for three weeks.Seru m fibrinogen level was examined before and after treatment. Compared with the control groups which were given antilipemia or (and) antiplatelet aggregation drugs, serum fibrinogen inlumbrokinase treated group significantly decreased two weeks after treatment in a time related manner 〔Before treatment (5.34 ±0.89) g/L,two weeks aftertreatment (4.33 ±1.09) g/L,three weeks after treatment (3.71 ±0.48) g/L〕. These results showed that lumbrokinase could relieve hyperfibrinogenemia,therefore the formation of thrombi would be decreased.Lum brokinase which had less side effects could be considered as a preventive drug of coronary atherogenesis disease.